Thalidomide-NH-PEG2-C2-NH-Boc is primarily utilized in the development of PROTACs (Proteolysis Targeting Chimeras), which are innovative molecules designed to target and degrade specific proteins within cells. This compound serves as a crucial linker component, connecting the thalidomide moiety, which binds to the E3 ubiquitin ligase, to a target protein ligand. The inclusion of the PEG2 spacer enhances solubility and flexibility, while the Boc group provides protection during synthesis. Its application is particularly significant in cancer research, where it aids in the selective degradation of oncogenic proteins, offering a potential therapeutic strategy for treating various malignancies. Additionally, it is employed in chemical biology studies to explore protein function and regulation.